Skip to main content
SpringerLink
Log in

Ankylosing Spondylitis

Current Approaches to Treatment

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

To date there is no definite cure for ankylosing spondylitis. However, modern treatment improves the quality of life and the final outcome for most patients. Patient education and physiotherapy form the basis of treatment. In pharmacotherapy, nonsteroidal anti-inflammatory drugs have a central role. Second-line drugs such as sulfasalazine, immunomodulating agents and other antirheumatic disease-modifying drugs should be applied if the disease is active. Corticosteroids are used mainly intra-articularly.

The problem of osteoporosis in ankylosing spondylitis is gaining more interest, and efforts to prevent or treat it will increase. It is critical to make an early diagnosis of ankylosing spondylitis and in active cases start intensive therapy before irreversible damage takes place.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gran JT, Husby G. Ankylosing spondylitis: current drug treatment. Drugs 1992; 44(4): 585–603

    Article  PubMed  CAS  Google Scholar 

  2. Gran JT, Husby G. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 1993; 22: 319–34

    Article  PubMed  CAS  Google Scholar 

  3. Yli-Kerttula T, Mötiönen T, Toivanen A. Different course of reactive arthritis in two HLA-B27 positive brothers with fatal outcome in one. J Rheumatol 1997; 24: 2047–50

    PubMed  CAS  Google Scholar 

  4. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993; 52: 174–6

    Article  PubMed  CAS  Google Scholar 

  5. Toivanen A, Khan MA. Therapeutic dilemmas in ankylosing spondylitis and related spondylarthropathies. Rheumatol Rev 1994; 3: 21–7

    Google Scholar 

  6. Ebringer A, Cox NL, Abuljadayel I, et al. Klebsiella antibodies in ankylosing spondylitis and Proteus antibodies in rheumatoid arthritis. Br J Rheumatol 1988; 27Suppl. II: 72–85

    PubMed  Google Scholar 

  7. Toivanen P. Microorganisms and the locomotor system. Klippel JH, Dieppe PA, editors. Rheumatology. 2nd ed. London: Mosby, 1998; section 4: 6.1–7.16

    Google Scholar 

  8. Mielants H, De Vos M, Veys EM. Clinical aspects of enterogenic arthropathies. Rheumatol Eur 1997; 26(1): 6–10

    Google Scholar 

  9. Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondyloarthropathy. Arthritis Rheum 1994; 37: 23–31

    Article  PubMed  CAS  Google Scholar 

  10. Bellamy N, Buchanan WW, Esdaile JM, et al. Ankylosing spondylitis antirheumatic drug trials. I. Effects of standardization procedures on observer dependent outcome measures. J Rheumatol 1991; 18: 701–8

    Google Scholar 

  11. Bellamy N, Buchanan WW, Esdaile JM, et al. Ankylosing spondylitis antirheumatic drug trials: II: Tables for calculating sample size for clinical trials. J Rheumatol 1991; 18: 1709–15

    PubMed  CAS  Google Scholar 

  12. Bellamy N, Buchanan WW, Esdaile JM, et al. Ankylosing spondylitis antirheumatic drug trials: III: setting the delta for clinical trials of antirheumatic drugs —results of a consensus development (Delphi) exercise. J Rheumatol 1991; 18: 1716–22

    PubMed  CAS  Google Scholar 

  13. Dougados M, Gueguen A, Nakache J-P, et al. Evaluation of a functional index for patients with ankylosing spondylitis. J Rheumatol 1990; 17: 1254–5

    PubMed  CAS  Google Scholar 

  14. Laurent MR, Buchanan WW, Bellamy A. Methods of assessment used in ankylosing spondylitis clinical trials: a review. Br J Rheumatol 1991; 30: 326–9

    Article  PubMed  CAS  Google Scholar 

  15. de Klerk E, van der Linden SJ. Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device. Br J Rheumatol 1996; 35: 60–5

    Article  PubMed  Google Scholar 

  16. Calin A, Elswood J. A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. J Rheumatol 1990; 17: 801–3

    PubMed  CAS  Google Scholar 

  17. Simon LS. Biologic effects on nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1997; 9: 178–82

    Article  PubMed  CAS  Google Scholar 

  18. McKenna F. Efficacy of diclofenac/misoprostol vs diclofenac in the treatment of ankylosing spondylitis. Drugs 1993; 45Suppl. 1: 24–30

    Article  PubMed  Google Scholar 

  19. Nissilä M, Lahesmaa R, Leirisalo-Repo M, et al. Antibodies to Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis in ankylosing spondylitis: effect of sulfasalazine treatment. J Rheumatol 1994; 21: 2028–7

    Google Scholar 

  20. Hannonen P, Möttönen T, Hakola M, et al. Sulfasalazine in early rheumatoid arthritis. Arthritis Rheum 1993; 11: 1501–9

    Article  Google Scholar 

  21. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis — a double blind controlled study in sixty patients. BMJ 1986; 293: 911–4

    Article  PubMed  CAS  Google Scholar 

  22. Feltelius N, Hallgren R. Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 1986; 45: 396–9

    Article  PubMed  CAS  Google Scholar 

  23. Nissilä M, Lehtinen K, Leirisalo-Repo M, et al. Sulphasalazine in the treatment of ankylosing spondylitis. Arthritis Rheum 1988; 31: 1111–6

    Article  PubMed  Google Scholar 

  24. Davis MJ, Dawes FT, Beswick E, et al. Sulphasalazine therapy in rheumatoid arthritis. Br J Rheumatol 1989; 28: 410–3

    Article  PubMed  CAS  Google Scholar 

  25. Fraser SM, Sturrock RD. Evaluation of sulphasalazine in ankylosing spondylitis — an interventional study. Br J Rheumatol 1990; 29: 37–9

    Article  PubMed  CAS  Google Scholar 

  26. Corkill MM, Jobanbutra P, Gibson T, et al. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Br J Rheumatol 1990; 29: 41–5

    Article  PubMed  CAS  Google Scholar 

  27. Ferraz MB, Tugwell P, Goldsmith CH, et al. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990; 17: 1482–6

    PubMed  CAS  Google Scholar 

  28. McConkey B. Sulphasalazine and ankylosing spondylitis. Br J Rheumatol 1990; 29: 2–5

    PubMed  CAS  Google Scholar 

  29. Taylor HG, Beswick PT, Dawes PT. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 1991; 10: 43–8

    Article  PubMed  CAS  Google Scholar 

  30. Kirwan J, Edwards A, Huitfelt B, et al. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 1993; 32: 729–33

    Article  PubMed  CAS  Google Scholar 

  31. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996; 39: 2004–12

    Article  PubMed  CAS  Google Scholar 

  32. Taggart A, Gardiner P, McEvoy F, et al. Which is the active moiety of sulfasalazine in ankylosing spondylitis? Arthritis Rheum 1996; 39: 1400–5

    Article  PubMed  CAS  Google Scholar 

  33. Chapman CM, Zwillich SH. Olsalazine in ankylosing spondylitis: a pilot study. J Rheumatol 1994; 21: 1699–701

    PubMed  CAS  Google Scholar 

  34. Handler RP. Favourable results using methotrexate in the treatment of patients with ankylosing spondylitis. Arthritis Rheum 1989; 32: 234

    Article  PubMed  CAS  Google Scholar 

  35. Yamane K, Saito C, Natsuda H, et al. Ankylosing spondylitis successfully treated with methotrexate. Intern Med 1993; 32: 53–6

    Article  PubMed  CAS  Google Scholar 

  36. Creemers MCW, van Riel PLCM, Franssen MJAM, et al. Second-line treatment in seronegative spondylarthropathies. Semin Arthritis Rheum 1994; 24: 71–81

    Article  PubMed  CAS  Google Scholar 

  37. Creemers MC, Franssen MJAM, van de Putte LB A, et al. Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 1995; 22: 1104–7

    PubMed  CAS  Google Scholar 

  38. Sadowska-Woblewska M, Garwolinska H, Maczynska-Rusiniak B. A trial of cyclophosphamide in ankylosing spondylitis with involvement of peripheral joints and high disease activity. Scand J Rheumatol 1986; 15: 259–64

    Article  Google Scholar 

  39. Steven MM, Morrison M, Sturrock RD. Penicillamine in ankylosing spondylitis: a double blind placebo controlled trial. J Rheumatol 1985; 12: 735–7

    PubMed  CAS  Google Scholar 

  40. Grasedyck K, Schattenkirchner M, Bandilla K. Zur Behandlung der Spondylitis ankylosans mit Auranofin (Ridaura). Z Rheumatol 1990; 49: 98–9

    PubMed  CAS  Google Scholar 

  41. Minz G, Enriquez RD, Mercado U. Intravenous methylprednisolone pulse therapy in severe ankylosing spondylitis. Arthritis Rheum 1981; 24: 734–6

    Article  Google Scholar 

  42. Richter MB, Woo P, Panayi GS. The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis. Clin Exp Rheumatol 1983; 53: 51–9

    CAS  Google Scholar 

  43. Ejstrup L, Peters ND. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Dan Med Bull 1985; 32: 231–3

    PubMed  CAS  Google Scholar 

  44. Husby G, Kass E, Spongsveen KL. Comparative double-blind trial of intra-articular injections of two long-acting forms of betamethasone. Scand J Rheumatol 1975; 4: 118–20

    Article  PubMed  CAS  Google Scholar 

  45. Braun J, Bollow M, Seyrekbasan F, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 1996; 23: 659–64

    PubMed  CAS  Google Scholar 

  46. Nissilä M, Anttila P, Hämäläinen M, et al. Comparison of chemical, radiation and surgical synovectomy for the knee joint synovitis. Scand J Rheumatol 1978; 7: 225–8

    Article  PubMed  Google Scholar 

  47. Donnelly S, Doyle DV, Denton A, et al. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994; 53: 117–21

    Article  PubMed  CAS  Google Scholar 

  48. Will R, Palmer R, Bhalla AK, et al. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet 1989; II: 1483–5

    Article  Google Scholar 

  49. Macdonald AG, Birkinshaw B, Durham B, et al. Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheumatol 1997; 36: 50–3

    Article  PubMed  CAS  Google Scholar 

  50. Amor B, Santos RS, Nahal R, et al. Predictive factors for the longterm outcome of spondylarthropathies. J Rheumatol 1994; 21: 1883–7

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Turku University, FIN-20520, Turku, Finland

    Auli Toivanen & Timo Möttönen

Authors
  1. Auli Toivanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timo Möttönen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Auli Toivanen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toivanen, A., Möttönen, T. Ankylosing Spondylitis. BioDrugs 10, 193–200 (1998). https://doi.org/10.2165/00063030-199810030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199810030-00003

Keywords

Search

Navigation